Clinical study on the treatment of COVID-19 by Qingfei Paidu Granule

Public Health Clinical Center of Chengdu0 个研究点开始时间: 待定最近更新: 2023年2月20日

试验速览

暂无简介。

•For the diagnosis of light and common COVID-19, refer to COVID-19 Diagnosis and Treatment Protocol (Trial Eighth Edition) (hereinafter referred to as Diagnosis and Treatment Protocol);Reference for asymptomatic infected persons: COVID-19 Control Plan (7th Edition)
•1. Conform to the diagnostic criteria of mild, common COVID-19 and novel Coronavirus asymptomatic infection in the two protocols mentioned above;
•2. To agree to participate in the study, the patient, legal guardian or the person in charge of the medical institution shall sign the informed consent through paper signature, mobile phone software electronic signature and voice authorization.

•1. Patients who cannot guarantee medication compliance during treatment and who are difficult to administer medication through oral nasal feeding;
•2. Patients with severe primary respiratory disease, or other pathogenic microbiological pneumonia that needs to be differentiated from COVID-19 or Novel Coronavirus asymptomatic infection;
•3. Patients with malignant tumors, mental diseases and other systemic malignancies who are considered unsuitable for the study by the investigator;
•4. People who have been allergic or intolerant to the test drug;
•5. Participating in other clinical trials.

发起方

Public Health Clinical Center of Chengdu